CClinicalTrials.gg
CompletedNCT01934296Activa PC+SUpdated Apr 24, 2023Results posted

Chronic Effects of DBS in Parkinson's Disease and Dystonia

An interventional study of Activa PC+S in Parkinson's Disease and Isolated Dystonia, sponsored by University of California, San Francisco. Completed at 1 site in United States. Open to participants aged 22 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-04-24.

Sponsored by University of California, San Francisco · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
22 Years to 75 Years
Sex
All
01

Study summary

The purpose of this study is to use an investigational device to record brain activity for 12-24 months following surgical implantation of deep brain stimulation (DBS) systems. The goal of the study is better understanding of brain activity in movement disorders and how they relate to DBS, not to bring new devices to market.

02

Conditions studied

  • Parkinson's Disease
  • Isolated Dystonia

Keywords

  • deep brain stimulation
  • cortical recording
  • neuroprosthesis
03

In context

Parkinson Disease

4,487 studies on the registry are indexed under Parkinson Disease; 1,082 are open to participants now.

This study's enrollment of 9 is below the median of 40 across 3,294 interventional studies indexed under Parkinson Disease.

Browse Parkinson Disease studies →

Lead sponsor

University of California, San Francisco is the lead sponsor of 2,132 studies on the registry; 375 are open to participants now.

Of its 262 completed or terminated interventional studies of FDA-regulated products, 196 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
22 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria(both groups):

  • Ability to give informed consent for the study
  • Movement disorder symptoms that are sufficiently severe, in spite of best medical therapy, to warrant surgical implantation of deep brain stimulators according to standard clinical criteria

Inclusion criteria (Isolated dystonia):

  • Age 22-75
  • Isolated dystonia that is generalized or segmental, that must affect one or - Stable doses of anti-dystonia medications (such as Artane, Baclofen, or Clonopin) for at least 30 days prior to baseline assessment
  • For patients with craniofacial involvement, prior treatment with botulinum toxin with failure to adequately control dystonia symptoms.

Inclusion criteria (PD):

  • Age 30-75
  • Bilateral disease (Hoehn and Yahr stage 2 or greater)
  • Has been treated with levodopa/carbidopa, and with a dopamine agonist, at the maximal tolerated doses as determined by a movement disorders neurologist
  • Stable doses of antiParkinsonian medications for at least 30 days prior to their baseline assessment
  • Significant disability in the setting of optimal medical management by a movement disorders neurologist. Disability may be due to tremor that is unresponsive to medications, or to motor fluctuations
  • UPDRS-III score off medication between 20 and 60
  • Improvement of at least 30% in the baseline UPDRS-III on medication score, compared to the baseline off-medication score.

Exclusion Criteria (both groups):

  • Pregnancy or breast feeding
  • MRI showing cortical atrophy out of proportion to age
  • MRI showing focal brain lesions that could indicate a non-idiopathic movement disorder,
  • Major comorbidity increasing the risk of surgery (prior stroke, severe hypertension, severe diabetes, or need for chronic anticoagulation other than aspirin)
  • Inability to comply with study follow-up visits
  • Any prior intracranial surgery
  • Mood depression with a Beck depression inventory score of > 17 on baseline screening
  • Significant cognitive impairment (MoCA\<25).
  • History of seizures
  • Immunocompromised
  • Has an active infection
  • Requires diathermy, electroconvulsive therapy (ECT) or transcranial magnetic - Has an implanted electronic device such as a neurostimulator, cardiac pacemaker or medication pump.
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    chronic brain recording

    This is a one-arm, single-center study of the neurophysiology of human movement disorders with two goals: 1) Assess the feasibility of chronic brain recording using a novel fully implantable pulse generator (Medtronic Activa PC+S), which has the capability of sensing and storing local field potentials (LFPs) recorded from implanted electrodes, in addition to providing therapeutic deep brain stimulation (DBS). 2) Study acute and chronic effects of therapeutic DBS on cortical LFPs. 3) Study feasibility of the use of brain signals as feedback either directly to the patient or for DBS stimulation adjustments.

    Device: Activa PC+S

Interventions

  • DeviceActiva PC+S

    Surgical implantation of Activa PC+S as one component of a therapeutic DBS system implantation

06

What researchers measure

Primary outcomes

  1. Number of Patients With Parkinson's Disease With Reliable Cortical and Sub-cortical Brain Signals

    To report number of PD patients with reliable cortical and subcortical brain signal recorded using Activa PC+S.

    Time frame: 24 months

07

Results

Posted Apr 24, 2023

Participant flow

Participant flow — Overall Study
MilestoneChronic Brain Recording
Started9
Completed9
Not completed0

Outcome measures

PrimaryNumber of Patients With Parkinson's Disease With Reliable Cortical and Sub-cortical Brain Signals

To report number of PD patients with reliable cortical and subcortical brain signal recorded using Activa PC+S.

Time frame:
24 months
Reported as:
Count of participants · Participants
Number of Patients With Parkinson's Disease With Reliable Cortical and Sub-cortical Brain Signals
ParticipantsChronic Brain Recording
Number of Patients With Parkinson's Disease With Reliable Cortical and Sub-cortical Brain Signals5

Adverse events

Collected over 2 years for each patient. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Chronic Brain Recording0/9 (0%)0/9 (0%)2/9 (22.2%)
Most frequent other events
Most frequent other events
EventChronic Brain Recording
Cerebrospinal Fluid (CSF) collected under scalpSurgical and medical procedures1/9
Fatigue after surgerySurgical and medical procedures1/9

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Chronic Brain Recording
<=18 years0
Between 18 and 65 years9
>=65 years0
Age, Continuous
Age, Continuous(years)Chronic Brain Recording
Mean57.44 ± 9.32
Sex: Female, Male
Sex: Female, Male(Participants)Chronic Brain Recording
Female3
Male6
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Chronic Brain Recording
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White9
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Chronic Brain Recording
United States9
08

Study locations

1 site
  • UCSF Surgical Movement Disorders Center
    San Francisco, California 94115, United States
09

References and documents

Publications

  • Swann NC, de Hemptinne C, Miocinovic S, Qasim S, Ostrem JL, Galifianakis NB, Luciano MS, Wang SS, Ziman N, Taylor R, Starr PA. Chronic multisite brain recordings from a totally implantable bidirectional neural interface: experience in 5 patients with Parkinson's disease. J Neurosurg. 2018 Feb;128(2):605-616. doi: 10.3171/2016.11.JNS161162. Epub 2017 Apr 14. PubMed 28409730 ↗

Study documents

  • Protocol and statistical analysis plan · Sep 14, 2017

Documents are hosted by the registry — open the source record to download them.

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01934296
Lead sponsor
University of California, San Francisco
Collaborators
Medtronic
Responsible party
Philip Starr (Professor, Neurological Surgery, University of California, San Francisco) — Principal investigator
First posted
Sep 4, 2013
Start date
Nov 2013
Primary completion
Dec 2021
Completion
Dec 2021
Results posted
Apr 24, 2023
Last update
Apr 24, 2023

Study contacts

Philip Starr, MD
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion